<DOC>
	<DOCNO>NCT01810393</DOCNO>
	<brief_summary>This open-label , randomize , multicenter study evaluate participant preference subcutaneous ( SC ) versus intravenous ( IV ) trastuzumab ( Herceptin ) participants HER2-positive metastatic breast cancer respond first-line treatment IV trastuzumab least 3 year . Participants randomize receive either 3 cycle ( cycle length = 21 day ) trastuzumab SC follow 3 cycle trastuzumab IV 3 cycle trastuzumab IV follow 3 cycle trastuzumab SC . All participant receive trastuzumab SC Cycles 7 18 . Anticipated time study treatment 1 year disease progression inacceptable toxicity occur , whichever come first .</brief_summary>
	<brief_title>A Study Assess Preference Subcutaneous Trastuzumab Treatment Participants With Human Epidermal Growth Factor Receptor ( HER ) 2-Positive Metastatic Breast Cancer Responding First-Line Intravenous Trastuzumab Least 3 Years</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically cytologically confirm HER2positive metastatic breast cancer On treatment firstline trastuzumab IV free disease progression least 3 year Left ventricular ejection fraction ( LVEF ) great equal ( &gt; /= ) 50 percent ( % ) Hormonal therapy allow Prior use antiHER2 therapy allow History malignancy , except curatively treat carcinoma situ cervix basal cell carcinoma participant curatively treat malignancy diseasefree least 5 year ; participant previous ductal carcinoma situ breast also eligible Participants severe dyspnea rest require supplementary oxygen therapy Serious cardiac illness medical condition would preclude use trastuzumab Hepatitis B , hepatitis C human immunodeficiency virus infection Pregnant lactate woman Concurrent enrollment clinical trial use investigational anticancer treatment , include hormonal therapy , biphosphonate therapy immunotherapy , within 28 day prior first dose study treatment Known hypersensitivity trastuzumab , murine protein , excipients Herceptin include hyaluronidase adhesive subcutaneous device , history severe allergic immunological reaction , example , difficult control asthma Central nervous system metastasis , unless treat stable least 3 year Inadequate organ function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>